Alnylam is in a sustained downtrend, with the stock declining 7.4% over the past year and currently trading at 298.76, which is just 60% of its 52-week range (52-week low: 273.11, high: 495.55). The price sits near the lower end of the range, suggesting bearish sentiment and potential value opportunity, but also risk of further downside if support breaks. The 1-year price change of -7.4% contrasts with the S&P 500's +20.6% gain, indicating significant relative underperformance. Short-term momentum shows a mixed picture: the 1-month change is +2.6%, while the 3-month change is -7.2%, indicating a recent bounce but still negative medium-term trend. The 1-month relative strength vs. SPY is -1.48, meaning the stock underperformed the market even during the bounce. The RSI is not provided, but the price action suggests a potential short-term recovery attempt within a longer-term downtrend. The 52-week low at 273.11 provides key support; a break below could signal further declines toward the 2025 lows. Resistance is at the 52-week high of 495.55, a level that seems distant given current momentum. Beta is 0.269, indicating the stock is significantly less volatile than the market, which may appeal to risk-averse investors but also limits upside in rallies. The current price is 9.4% above the 52-week low, suggesting some support, but the stock remains 39.7% below the 52-week high.

Revenue growth has been exceptional, with Q4 2025 revenue of $1.097 billion representing 84.95% year-over-year growth, driven by strong commercial execution across the portfolio. However, the trajectory shows some deceleration from Q3 2025's $1.249 billion, though Q3 included a one-time partner milestone. The trailing twelve-month revenue run-rate is approximately $3.51 billion, with key products like Givlaari ($160.7M) and Onpattro ($70.8M) contributing. The growth is fueled by expanding patient populations and new launches, but investors should monitor for sustainability as competition emerges. Profitability has turned positive: Q4 2025 net income was $186.4 million (EPS $1.41), a dramatic improvement from a net loss of $83.8 million in Q4 2024. Gross margin remains strong at 75.6% in Q4 2025, though slightly compressed from 84.2% in Q3 2025 due to product mix. Operating margin improved to 12.0% in Q4 2025 from negative levels a year ago, indicating operating leverage. The company is now generating positive net income, a critical milestone for a biotech firm. The balance sheet is solid: cash and equivalents of $1.66 billion as of Q4 2025, with free cash flow of $140.3 million in Q4 2025 and $465.4 million TTM. Debt-to-equity is 1.62, manageable given the cash position, and the current ratio of 2.76 indicates ample liquidity. ROE is 39.8%, reflecting strong profitability relative to equity, though this is partly due to leverage. The company is self-funding operations and growth, reducing reliance on external financing.